Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...

Principles of Pharmacogenetics: Types of Genetic Variants

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...

Chronic Kidney Disease III: Interprofessional Care

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...

Genetic Screens

Genetic Screens

Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Whole genome sequencing for CKD of unexplained cause in Hong Kong.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026

Same authorSame journal

Autosomal Dominant Polycystic Kidney Disease: Genetic Insights, Phenotypic Spectrum, and Advances in Prognosis and Treatment.

Advances in kidney disease and health·2026

Same author

Progression of Cardiovascular-Kidney-Metabolic Syndrome among Hispanics/Latinos in the United States: The Hispanic Community Health Study/Study of Latinos (HCHS/SOL).

Clinical journal of the American Society of Nephrology : CJASN·2026

Same author

Identification of DNA methylation signatures of smoking in women and associations with cardiovascular disease mortality.

Communications biology·2026

Same author

Smoking drives an epigenetic memory of aberrant hematopoiesis.

medRxiv : the preprint server for health sciences·2026

Same author

Population-scale genomic medicine with the Hong Kong Genome Project.

Nature medicine·2026

Same journal

Fabry Disease: Current Perspectives on Diagnosis and Management Strategies.

Advances in kidney disease and health·2026

Same journal

After the Diagnosis.

Advances in kidney disease and health·2026

Same journal

Collagen Genes-Related Glomerular Disease.

Advances in kidney disease and health·2026

Same journal

Genetic Nephrotic Syndrome in Children and Adolescents: An Update.

Advances in kidney disease and health·2026

Same journal

Genetic and Clinical Evaluation of Pediatric Cystic Kidney Diseases: Autosomal Dominant and Autosomal Recessive Polycystic Kidney Disease.

Advances in kidney disease and health·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 24, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

Incorporating Genetics Into Nephrology Practice-The New National Kidney Foundation Guidelines for Genetic Testing.

Becky Mingyao Ma¹, Nora Franceschini²

¹Division of Nephrology, Department of Medicine, Queen Mary Hospital, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong Special Administrative Region, China.

Advances in Kidney Disease and Health

|June 22, 2026

Summary

This summary is machine-generated.

Genetic testing for chronic kidney disease aids diagnosis, prognosis, and family planning. This review summarizes guidelines for genetic testing in kidney disease patients and at-risk individuals, focusing on monogenic disorders and APOL1.

Keywords:

APOL1 Clinical care Genetic testing Monogenic disorders

More Related Videos

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

Related Experiment Videos

Last Updated: Jun 24, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

Area of Science:

Nephrology
Medical Genetics
Genomics

Background:

Chronic kidney disease (CKD) has a significant genetic component.
Genetic factors influence disease progression, treatment response, and heritability.
Understanding genetic contributions is crucial for personalized patient care and family risk assessment.

Purpose of the Study:

To summarize the National Kidney Foundation's report on genetic testing for kidney diseases.
To provide guidance on genetic testing for patients with CKD and at-risk individuals, including family members and donors.
To highlight the role of genetic testing in managing monogenic kidney disorders and APOL1 nephropathy.

Main Methods:

Literature review of the National Kidney Foundation report.
Focus on monogenic kidney disorders and APOL1 gene variants.
Case-level interpretation to illustrate medical decision-making.

Main Results:

Genetic testing can inform diagnosis, prognosis, and therapeutic strategies for kidney disease.
Testing is valuable for guiding kidney transplant planning.
Genetic information aids in assessing risks for relatives and in family planning.

Conclusions:

Genetic testing is an integral tool in the comprehensive management of kidney diseases.
Application of genetic testing extends to patients, at-risk relatives, and potential kidney donors.
Guidelines support the use of genetic testing for monogenic disorders and APOL1-associated nephropathies to improve patient outcomes.